The Vanguard Group, Inc. has recently announced that it has increased stake in Reata Pharmaceuticals Inc. (NASDAQ:RETA) by 1.56%. After grabbing 2.68 million shares, the institutional investor is now in possession of 41110.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 8.34% having worth around $264.8 million. Moreover, Perceptive Advisors LLC increased its share by 2.17 million to have a control over 2.17 million shares. And Deep Track Capital LP raised its holdings to 0.73 million shares by acquiring 0.73 million shares or 2.27% of the stake.
Reata Pharmaceuticals Inc. (RETA) concluded trading on 05/25/23 at a closing price of $92.54, with 1.08 million shares of worth about $99.71 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 159.58% during that period and on Thursday the price saw a loss of about -2.96%. Currently the company’s common shares owned by public are about 36.95M shares, out of which, 30.57M shares are available for trading.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 70 times over the past 12 months. They bought 500,817 shares in 29 of the transactions. In 41 selling transactions, insiders dumped 344,168 shares.
Vanguard Health Care Fund, Vanguard Total Stock Market ETF, and Vanguard Small Cap Index Fund are the top 3 mutual funds which are holding stakes in Reata Pharmaceuticals Inc. Vanguard Health Care Fund is currently holding 1.24 million shares of worth totaling $122.31 million. The company recently came buying 0.0 shares which brought its stake up to 3.85% of the company’s outstanding shares. Vanguard Total Stock Market ETF bought 7836.0 shares, after which its hold over company’s outstanding shares expand to 2.62%, leaving 0.84 million shares with the mutual fund that have a worth of about $83.16 million. Vanguard Small Cap Index Fund, after selling 0.71 million shares, have now control over 2.20% of the stake in the company. It holds 174.0 shares of worth $69.76 million.
Reata Pharmaceuticals Inc. (NASDAQ: RETA) started trading at $95.19, below -$0.17 from concluding price of the previous day. However, the stock later moved at a day high price of 95.72, or with a loss of -2.96%. Stock saw a price change of 13.98% in past 5 days and over the past one month there was a price change of -5.44%. Year-to-date (YTD), RETA shares are showing a performance of 143.59% which increased to 241.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $18.47 but also hit the highest price of $106.69 during that period. The average intraday trading volume for Reata Pharmaceuticals Inc. shares is 1.44 million. The stock is currently trading 0.21% above its 20-day simple moving average (SMA20), while that difference is down -0.31% for SMA50 and it goes to 81.17% higher than SMA200.
The Vanguard Group, Inc. acquired 2.68 million shares of Reata Pharmaceuticals Inc. having value of about $264.8 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 41110.0 shares in the company valued at close to $3804319.4, or have control over 1.56% stake in the company. Reata Pharmaceuticals Inc. (NASDAQ: RETA) currently have 36.95M outstanding shares and institutions hold larger chunk of about 89.30% of that. Holding of mutual funds in the company is about 28.44% while other institutional holders and individual stake holders have control over 51.53% and 24.59% of the stake respectively.
The stock has a current market capitalization of $3.53B and its 3Y-monthly beta is at 1.54. It has posted earnings per share of -$9.65 in the same period. It has Quick Ratio of 6.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RETA, volatility over the week remained 6.20% while standing at 5.37% over the month.
Analysts are in expectations that Reata Pharmaceuticals Inc. (RETA) stock would likely to be making an EPS of -$2.84 in the current quarter, while forecast for next quarter EPS is -$2.44 and it is -$4.33 for next year. For the current quarter EPS, analysts have given the company a lowest target -$3.39 which is -$2.47 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$2.02 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -4.30% while it is estimated to increase by 57.90% in next year.
